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ABSTRACT 
Purpose of the review: Chronic kidney disease is common, associated with increased 
cardiovascular risk, and frequently complicated by hypertension requiring multiple agents for 
control. Thiazides are naturally attractive for use in this population, unfortunately they are 
classically thought to be ineffective in advanced chronic kidney disease based on both 
theoretical considerations and the earliest studies of these agents. This report reviews the 
studies of thiazide use in chronic kidney disease since the 1970s, including 5 randomized 
controlled trials, all of which report at least some degree of efficacy. 
Recent findings: Two recent studies add further evidence for the utility and efficacy of 
thiazides in chronic kidney disease. Of these two, one uses gold standard ambulatory blood 
pressure monitoring in patients with poorly controlled hypertension and advanced chronic 
kidney disease and found chlorthalidone reduces blood pressure. The second is the largest 
study to date of thiazides in chronic kidney disease; adding a fixed low-dose chlorthalidone as 
the first diuretic to the antihypertensive regimen improved blood pressure. 
Summary: These numerous small but positive studies reinforce the need for a 
randomized trial to demonstrate safety and efficacy of thiazides in advanced chronic kidney 
disease. 
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INTRODUCTION 
Chronic kidney disease (CKD) is a common diagnosis of major public health importance. 
Defined as the presence of kidney damage or abnormal kidney function over a span of at least 
three months [1], CKD has a prevalence of 13.6% in the United States making it more common 
than diabetes mellitus [2]. Furthermore, CKD is strongly associated with cardiovascular events 
[3] with the presence of CKD increasingly recognized as a coronary heart disease equivalent, 
similar to diabetes [4]. This enhanced cardiovascular risk increases with worsening stage of 
CKD, and the prevalence of advanced CKD with glomerular filtration rate (GFR) below 30 
mL/min/1.73 m2 is estimated at 0.62% of the population2. 
In light of the high prevalence and associated cardiovascular complications of CKD, 
efforts to mitigate modifiable risk factors such as hypertension are needed. Indeed, 
hypertension is very common in CKD with a prevalence of 86% in a recent Chronic Renal 
Insufficiency Cohort (CRIC) report [5]. Notably, 58% of hypertensive CRIC patients were on 
treatment with at least 3 antihypertensive medications. Similarly, a recent prospective cohort 
study of 436 CKD patients employing ambulatory blood pressure monitoring (ABPM) found 
resistant hypertension to be prevalent in 23% [6], emphasizing the difficulty of controlling BP in 
this population.  
Thus control of hypertension is a primary concern in a large proportion of the CKD 
population and multiple medications are frequently necessary for adequate treatment. With a 
limited number of drug classes in the antihypertensive armamentarium, the use of thiazide 
diuretics is an attractive option. Unfortunately, for decades the conventional wisdom has been 
that thiazides are ineffective in advanced CKD and thus these medications are often overlooked 
in the CKD population; this thought still prevails. This review will examine the history of thiazide 
diuretic use in CKD, current guidelines, and the evidence for efficacy of thiazide use in 
advanced CKD. Notably, this review will update on recent reviews of this topic [7;8], with a 
particular focus on the latest evidence from the last year. 
 
THIAZIDE BACKGROUND  
 By definition thiazides are all derivatives of benzothiadiazine, which include 
chlorothiazide, hydrochlorothiazide, and bendroflumethiazide. Other agents that are 
pharmacologically similar are properly termed thiazide-like diuretics, which include metolazone, 
chlorthalidone, and indapamide. In this review “thiazides” refers both to benzothiadiazine 
derivatives and to thiazide-like diuretics, which is consistent with common practice. 
Thiazides were the first category of effective oral antihypertensive drugs with an 
acceptable safety profile, and they have remained in clinical use since their discovery in the 
1950s [9]. Thiazides improve cardiovascular endpoints including stroke, heart failure, coronary 
events, and death across numerous trials [10;11]. Considering the classical importance of 
volume overload to the pathogenesis of hypertension in kidney disease [12], thiazides are 
ostensibly an attractive agent to use in CKD. However, for as long as thiazides have been in 
clinical use there has been concern that they may be ineffective in advanced CKD.  
The reasons for this are both theoretical and empirical. Firstly, the primary site of action 
for thiazides is the Na+/Cl- cotransporter (NCC) in the distal convoluted tubule of the nephron, 
which is responsible for only 5% of total filtered sodium reabsorption. Thus in advanced CKD 
where GFR falls leading to reduced filtration of sodium, the presumption has been that inhibiting 
such a small fraction of total sodium reabsorption would be clinically insignificant. Secondly, 
small early studies of chlorothiazide in CKD appeared to support the theoretical concerns 
[13;14]. One such trial from 1961 epitomizes the early evidence base [14]. In this study 
chlorothiazide 500 mg was administered intravenously once to subjects who were then closely 
monitored for the subsequent 3 hours while on a constant intravenous saline infusion [14]. Urine 
flow and the sodium excretion rate increased in all 7 subjects with inulin clearance 60 mL/min or 
less. However, the 2 subjects with the lowest clearances at 6 and 11 mL/min did not have as 
great an improvement in urine flow or sodium excretion as the others. Based on these results, 
the authors concluded that thiazide efficacy is reduced in the setting of very low GFR. However, 
it should be noted that more recent investigators have suggested that the antihypertensive 
effect of thiazides may be due to a direct vasodilator effect [15;16], which may in part explain 
the positive findings below. 
 
GUIDELINES ON THIAZIDE USE IN CKD 
Based on such qualified conclusions from early studies, a consensus developed that 
thiazide diuretics were ineffective in advanced CKD, and while there have been 
acknowledgments that the evidence wasn’t definitive [17], the dogma hardened and became 
reflected in influential guidelines. However, more recently guidelines on the use of thiazides in 
advanced CKD have been less prescriptive. For example, the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC7) recommended changing from thiazide to loop diuretics [18] when estimated 
GFR falls below 30 mL/min/1.73 m2, but the recently promulgated JNC8 recommendations take 
no position on the use of thiazides versus loop diuretics in CKD [19].  
 Similarly, the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative 
(KDOQI) recommends switching from thiazides to loop diuretics [20] when estimated GFR falls 
below 30 mL/min/1.73 m2, while the more recent Kidney Disease Improving Global Outcomes 
(KDIGO) guidelines are less dogmatic [21]. The KDIGO guidelines acknowledge that while 
many clinicians switch from thiazides to loop diuretics, the antihypertensive benefit of thiazides 
may still be preserved at low levels of GFR. 
  
OLDER STUDIES OF THIAZIDES IN CKD 
 
 Starting in the 1970s numerous small trials began to show both diuretic and 
antihypertensive effects of varied thiazides in CKD. As detailed in Table 1, these early studies 
included 5 small heterogeneous trials of metolazone in CKD all with a before-and-after design 
[22-26], and in general GFR was low with 2 trials reporting creatinine clearances for individual 
subjects as low as 1 mL/min. These studies showed an improvement in reported diuretic or 
antihypertensive outcomes with metolazone administration, and these early positive results are 
likely the reason that there is a persistent belief that metolazone is the unique thiazide that is 
effective in advanced CKD [27]. 
 Two small trials from the 1980s with alternative thiazides showed further evidence of 
efficacy in advanced CKD. The first included 8 hypertensive patients with mean serum 
creatinine 3.31 mg/dL and all subjects were treated with furosemide and hydrochlorothiazide 
leading to significantly reduced body weight, plasma volume, and BP [28]. The second trial 
enrolled 15 hypertensive subjects including 5 with CKD and mean creatinine clearance of 37 
mL/min1.73 m2 who were all treated with escalating doses of indapamide, and those subjects 
with CKD had significantly greater reduction in body weight and similar reduction in BP as 
compared to those subjects with normal renal function [29]. 
 Importantly, 5 randomized controlled trials (RCT) reported between 1979 and 2012 have 
investigated thiazide efficacy in CKD[30-34], also detailed in Table 1. The earliest was a double 
blind crossover study that enrolled 16 woman with mean creatinine clearance of 14 mL/min/1.73 
m2 who were treated with chlorothiazide 500 mg twice daily or placebo for 6 weeks before 
crossover [30]. Seven patients were withdrawn by protocol, but chlorothiazide significantly 
reduced BP in the 9 subjects that completed the study. 
 Two similar RCTs from the 1990s investigated natriuresis due to thiazides, loop 
diuretics, or the combination in a single blind, crossover fashion. The first enrolled 10 subjects 
with mean inulin clearance 13 mL/min/1.73 m2 who were treated with single intravenous doses 
of either a loop diuretic alone or combined with intravenous isobutyl hydrochlorothiazide; the 
combination significantly increased sodium excretion [31]. The second RCT enrolled 19 subjects 
with average creatinine clearance 39 mL/min and treated them with single oral doses of either a 
loop diuretic, or oral hydrochlorothiazide, or the combination of the two.  This trial found that 
while the loop diuretic and hydrochlorothiazide individually increased sodium excretion, the 
combination was subsequently significantly more potent [32]. 
 In the last 10 years Dussol and colleagues performed two similar double blind RCTs of 
thiazides in CKD, both also with a crossover design [33;34]. The first RCT enrolled 7 subjects 
with average measured GFR of 25 mL/min who were randomized to either oral furosemide 60 
mg daily or oral hydrochlorothiazide 25 mg daily for 30 days. After washout they then crossed 
over to the other drug.  Finally, they received 30 day period of combination therapy [33]. The 
second RCT was reported in 2012 and enrolled 23 subjects with measured GFR of 25 mL/min 
[34]. This second RCT used the same doses of both medications, but the intervention periods 
were each 90 days long. Both RCTs found furosemide and hydrochlorothiazide individually 
significantly and similarly reduced mean arterial BP with the combination of diuretics more 
potent in the larger study for a reduction of 15 mmHg. 
 
RECENT STUDIES OF CHLORTHALIDONE IN CKD 
 The positive studies of thiazides in CKD above have included most clinically available 
examples of the drug class including chlorothiazide, metolazone, hydrochlorothiazide, and 
indapamide. However, the absence of chlorthalidone is conspicuous as there is ample direct 
RCT evidence for the benefit of chlorthalidone in the general hypertensive population including 
from the Systolic Hypertension in the Elderly Program (SHEP) trial [35] and the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [36]. More recently, post 
hoc analyses of the Multiple Risk Factor Invention Trial (MR FIT) suggest that chlorthalidone 
may be superior to hydrochlorothiazide for regression of left ventricular hypertrophy [37] and 
reduction of cardiovascular events [38]. It is in this context that two trials of chlorthalidone in 
CKD published in the last year merit close attention. 
 Both studies were uncontrolled trials using a before and after design. The first was a 
pilot study of subjects recruited for estimated GFR between 20 and 45 mL/min/1.73 m2 and 
poorly controlled hypertension defined as average BP ≥ 135/85 mmHg on ABPM despite 
treatment [**39]. The antihypertensive regimen for all subjects was standardized to lisinopril 20-
40 mg/day, atenolol 50-100 mg daily, amlodipine 10 mg daily, and torsemide 10-20 mg daily 
based on the original clinical regimen while doses of other antihypertensive drug classes were 
left unchanged. After confirmation of uncontrolled hypertension by ABPM on the standardized 
regimen, the open label forced titration intervention was started with chlorthalidone 25 mg daily 
and the dose was increased on subsequent visits up to a maximum of 100 mg daily over the 12 
week trial unless the subject had symptomatic hypotension, a drug related adverse event, or 
average home systolic BP < 125 mmHg. 
 12 of 14 subjects completed the study; one subject withdrew consent after 2 days of 
treatment and another was excluded per protocol 2 weeks into treatment due to home BP 
persistently elevated > 160/100 mmHg [**39]. All subjects were male, average age was 67.5 
years, 8 of 14 were African American race, average estimated GFR was 27 mL/min/1.73 m2, 
and average 24 hour ambulatory BP was 143/75 mmHg despite a mean of 3.8 antihypertensive 
drugs at the end of the run-in phase. 
 Modeled mean chlorthalidone dose was 51 mg daily at the last visit, and there was a 
significant reduction of 10.5 mmHg in average 24 hour ambulatory systolic BP from baseline 
[**39]. Both total body volume measured by air displacement plethysmography and body weight 
were significantly reduced by 1.5 L and 1.2 kg from baseline respectively. This study is 
important for employing the gold standard of ABPM to show that the addition of chlorthalidone to 
a clinically significant hypertensive regimen in patients with advanced CKD may be effective at 
reducing BP as mediated by volume reduction. 
 The second chlorthalidone trial recruited subjects with estimated GFR < 60 mL/min/1.73 
m2 and poorly controlled hypertension defined as office BP ≥ 140/90 mmHg despite treatment 
with nondiuretic medications [**40]. After enrollment, subjects were started on a fixed dose of 
chlorthalidone 25 mg daily while other antihypertensive drugs were unchanged, and they were 
followed for 8 weeks of study. 
Fully 58 of 60 subjects completed the study, the 2 drop outs having stopped 
chlorthalidone outside the protocol [**40]. Average age was 57 years, 60% of subjects were 
male,  average estimated GFR was 39 mL/min/1.73 m2, and average office was BP 151/90 
despite a mean of 1.8 non-diuretic antihypertensive drugs at baseline. 
At the final visit, office systolic BP and body weight were both significantly reduced from 
baseline by 19 mmHg and 0.88 kg respectively [**40]. Importantly, both the subgroups of 28 
subjects with estimated GFR 30 to 44 mL/min/1.73 m2 and 9 subjects with estimated GFR 15 to 
29 mL/min/1.73 m2 had similar reductions in systolic BP at 19 and 20 mmHg respectively. This 
study is important for being the largest by the factor of 3 to investigate thiazide use in CKD, and 
for showing that even fixed lower dose chlorthalidone may be effective at reducing office BP as 
a first diuretic for hypertension in CKD. 
It is important to note that laboratory abnormalities and adverse events were common in 
both studies with 50% of subjects in the forced titration study of 14 subjects with advanced CKD 
[**39] and in 15% of patients in the fixed dose study with less severe CKD [**40]. Not 
surprisingly, the most frequent complications in both studies were hypokalemia, hyponatremia, 
and hyperuricemia. 
 
CONCLUSION 
The early observation that thiazide potency is reduced in advanced CKD is 
uncontroversial, especially as it has since been widely recognized that loop diuretic potency too 
is reduced in advanced CKD [41]. However, that early observation developed into dogma 
reinforced by influential guidelines that thiazides are ineffective in advanced CKD. Over the 
span of decades varied small studies using multiple different thiazides and including 5 RCTs 
have challenged that dogma by showing thiazides to be effective alone or in combination with a 
loop diuretic even in advanced CKD with GFR < 30 mL/min/m2. Most recently, two studies 
further add to the evidence for clinical utility and efficacy based on their use of chlorthalidone in 
advanced CKD for the first time, for the use of gold standard ABPM to assess hypertension, and 
for a large study size relative to prior trials. 
The time has come to perform a randomized trial of safety and efficacy of thiazides on 
top of existing antihypertensive among hypertensive people with advanced CKD. 
● Thiazides have been shown to be effective for reducing blood pressure in advanced chronic 
kidney disease in small studies, including randomized trials. 
 
● Thiazides have been shown to be effective for natriuresis in advanced chronic kidney disease 
in small studies, including randomized trials. 
 
● Most clinically available thiazides have direct evidence for efficacy in advanced chronic kidney 
disease, not just metolazone. 
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Table 1: Chronological list of studies of thiazides in CKD  
 
Author Year Number 
of CKD 
subjects 
Baseline 
kidney function 
Design Protocol Diuretic effect BP Effect 
Dargie 1972 14 Mean Cr 
clearance 4.2 
mL/min 
Before-After Single oral dose of 
metolazone given 
ranging from 20-
150 mg.    
Significant increase in 
urine flow and sodium 
excretion.  
Not reported. 
Bennett 1973 17 Mean Cr 
clearance 33 
mL/min 
Before-After Oral metolazone 5 
mg daily titrated 
up to maximum 25 
mg over 3 months. 
Weight reduced 1.3 kg 
and edema improved. 
Diastolic BP reduced 
by 12.5 mmHg 
among 12 subjects 
who were 
hypertensive. 
Craswell 1973 12 Mean Cr 
clearance 38 
mL/min among 
8 subjects, 
remaining 4 
subjects had 
mean serum 
Cr 8.4 mg/dL 
Before-After Oral metolazone 
given in doses 
ranging from 2.5 to 
25 mg daily over 
2-20 weeks. 
Weight reduced 1.4 kg 
and edema improved. 
BP reduced by 
14.2/3.2 mmHg. 
Dargie 1974 6 "GFR" in 6 
CKD patients 
ranged from 1-
7 mL/min 
Before-After Oral metolazone 
given in doses of 5 
mg to 200 mg 
daily for 7-180 
days. 
Weight reduced 3.8 kg. Not reported. 
Paton 1977 10 Mean Serum 
Cr 4.9 mg/dL 
Before-After Oral metolazone 
given between 2.5 
mg and 30 mg 
daily over mean 
13 weeks. 
Weight reduced 2.0 lbs. BP reduced by 15/8 
mmHg. 
Jones 1979 16 Mean Cr 
clearance 14 
mL/min 
Double blind 
placebo 
controlled 
crossover 
RCT 
Oral chlorothiazide 
500 mg twice daily 
versus placebo for 
6 week periods. 
No difference in weight 
reduction. 
BP reduced 
significantly by 13/6 
mmHg. 
Wollam 1982 8 Mean serum 
Cr 3.3 mg/dL 
Before-After Hydrochlorothiazid
e 25 to 50 mg 
twice daily added 
to furosemide up 
to 480 mg daily. 
Weight and plama 
volume both significantly 
reduced by 2.6 kg and 
volume by 370 mL 
respectively. 
Addition of 
hydrochlorothiazide 
significantly reduced 
BP by 22/11 mmHg.  
Leenen 1988 5 Mean Cr 
clearance 37 
mL/min 
Single blind 
forced 
titration 
study 
Placebo or 
indapamide 1.5 
mg, 2.5 mg, or 5 
mg given daily for 
4 week periods. 
Weight significantly 
reduced by 1.9 kg. 
BP reduced. 
Fliser 1994 10 Mean inulin 
clearance 13 
mL/min /1.73 
m2 
Single blind 
placebo 
controlled 
crossover 
RCT 
Single intravenous 
doses of 
torsemide 50 mg + 
placebo versus 
torsemide 50 mg + 
buthiazide 20 mg. 
Combination 
significantly increased 
sodium excretion by 134 
mEq/day. 
Not reported. 
Knauf 1995 19 Mean Cr 
clearance 39 
mL/min 
Single blind 
placebo 
controlled 
crossover 
RCT 
Single oral doses 
of 
hydrochlorothiazid
e 25 mg or 50 mg 
versus single oral 
doses of 
furosemide 40 mg 
or 80 mg versus 
combination of 
hydrochlorothiazid
e 25 mg + 
furosemide 40 mg. 
Combination 
significantly increased 
sodium excretion by 
141.5 mEq/day. 
Not reported 
Dussol 2005 7 Mean DTPA 
clearance 25 
mL/min/1.73m2 
Double blind 
crossover 
RCT, open 
label 
combination 
Oral 
hydrochlorothiazid
e 25 mg daily 
versus furosemide 
60 mg daily versus 
combination for 30 
day periods. 
No differences in weight 
reduction or 24 hour 
sodium excretion. 
All 3 regimens 
significantly reduced 
mean arterial BP by 
12-15 mmHg from 
baseline. 
Dussol 2012 23 Mean DTPA 
clearance 25 
mL/min/1.73m2 
Double blind 
crossover 
RCT, open 
label 
combination 
Oral 
hydrochlorothiazid
e 25 mg daily 
versus furosemide 
60 mg daily versus 
combination for 90 
day periods. 
No differences in 24 
hour sodium excretion. 
Furosemide significantly 
reduced weight by 4 kg, 
hydrochlorothiazide 
reduced weight 
nonsignificantly by 2 kg, 
and the combination had 
a significant reduction of 
3 kg. 
Hydrochlorothiazide 
and furosemide both 
significantly reduced 
mean arterial BP by 7 
and 8 mmHg 
respectively. The 
combination had a 
significant reduction 
of 15 mmHg. 
Agarwal 2014 14 Mean 
estimated GFR 
27 
mL/min/1.73m2 
Before-After 
forced 
titration 
study on top 
of 
standardize
d 
antihyperten
sive 
regimen 
Forced titration 
study of oral 
chlorthalidone 25 
mg to 100 mg 
daily for 12 weeks.  
Body weight and total 
body volume reduced 
significantly by 1.2 kg 
and 1.5 L, respectively. 
Ambulatory systolic 
BP significantly 
reduced by 10.5 
mmHg. 
Cirillo 2014 60 Mean 
estimated GFR 
39 
mL/min/1.73m2 
Before-After 
fixed dose 
study on top 
of existing 
anthyperten
sive therapy 
Fixed dose study 
of oral 
chlorthalidone 25 
mg daily for 8 
weeks. 
Body weight reduced 
significantly by 0.88 kg. 
Office systolic BP 
significantly reduced 
by 19 mmHg. 
 
 
 
  
Table legend: CKD, chronic kidney disease; BP, blood pressure; Cr, creatinine; GFR, glomerular filtration rate; RCT, randomized 
clinical trial. 
 
 
 
